MedTrace Logo

Excimer Laser With Topical Agents in Psoriasis Vulgaris

NCT05555797 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-18

No results posted yet for this study

Summary

Psoriasis is a chronic, immune-mediated disease that affects approximately 2% of the population. The development and exacerbation of psoriasis involve an interaction between multiple genetic and environmental risk factors.

Conditions

Interventions

DEVICE

308nm Excimer laser

Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)

DRUG

Tazarotene Topical Gel

Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks

DRUG

Betamethasone Valerate

.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-30
Primary Completion
2023-09-30
Completion
2023-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05555797 on ClinicalTrials.gov